Further press reviews can be found in the German section of this website.

08.08.2005

Licensing agreement for markers for vascular diseases

Dade Behring, the University of Frankfurt and the university's innovation provider Innovectis have signed a licensing agreement for markers for vascular dieseases.

Dade Behring has gained an exclusive worldwide licence for the combined use of certain markers for diagnosing vascular diseases.

Following an agreement with the University of Frankfurt and the university's innovation provider Innovectis, the Deerfield, Illinois firm obtained rights to the combined use of soluble fms-like tyrosine kinase 1 (sFit) and placental growth gactor (PIGF).

Download [101 KB]
Source: INNOVECTIS GmbH, CLINICA 1162 June 24 2005

Further information:
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH